Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 528

Results For "CE"

9359 News Found

Roquette completes acquisition of IFF Pharma Solutions
News | May 05, 2025

Roquette completes acquisition of IFF Pharma Solutions

The transaction enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide


Ami Organics Q4 FY25 PAT up at Rs. 62.48 Cr
News | May 05, 2025

Ami Organics Q4 FY25 PAT up at Rs. 62.48 Cr

The company has posted net profit of Rs. 158.71 crores for the Financial Year ended March 31, 2025


Tatva Chintan Pharma Chem reports consolidated Q4 FY25 PAT at Rs. 1.03 Cr
News | May 05, 2025

Tatva Chintan Pharma Chem reports consolidated Q4 FY25 PAT at Rs. 1.03 Cr

The company has posted net profit of Rs.5.71 crores for the Financial Year ended March 31, 2025


Biocon Biologics secures strong market coverage for Yesintek in US
News | May 05, 2025

Biocon Biologics secures strong market coverage for Yesintek in US

Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025


Thyrocare launches diagnostic lab in Bhagalpur
Healthcare | May 03, 2025

Thyrocare launches diagnostic lab in Bhagalpur

30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond


USFDA inspection at Concord Biotech’s API facility at Dholka
Drug Approval | May 03, 2025

USFDA inspection at Concord Biotech’s API facility at Dholka

These observations are procedural in nature and none of them are related to data integrity


Sanofi Consumer Healthcare India Q1 PAT up 12.9%
News | May 03, 2025

Sanofi Consumer Healthcare India Q1 PAT up 12.9%

The Q1 2025 also witnessed a successful launch of Allegra D


Strides acquires identified ANDAs from Nostrum Laboratories, USA
News | May 03, 2025

Strides acquires identified ANDAs from Nostrum Laboratories, USA

The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs


AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Clinical Trials | May 03, 2025

AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease